KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Return on Invested Capital (2019 - 2024)

Historic Return on Invested Capital for Xenon Pharmaceuticals (XENE) over the last 7 years, with Q3 2025 value amounting to 0.58%.

  • Xenon Pharmaceuticals' Return on Invested Capital fell 2700.0% to 0.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.58%, marking a year-over-year decrease of 2700.0%. This contributed to the annual value of 0.34% for FY2024, which is 800.0% down from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Return on Invested Capital stood at 0.58%, which was down 2700.0% from 0.48% recorded in Q2 2025.
  • Xenon Pharmaceuticals' Return on Invested Capital's 5-year high stood at 0.13% during Q2 2022, with a 5-year trough of 0.58% in Q3 2025.
  • For the 5-year period, Xenon Pharmaceuticals' Return on Invested Capital averaged around 0.28%, with its median value being 0.26% (2021).
  • Its Return on Invested Capital has fluctuated over the past 5 years, first surged by 1200bps in 2022, then tumbled by -2700bps in 2025.
  • Xenon Pharmaceuticals' Return on Invested Capital (Quarter) stood at 0.2% in 2021, then increased by 11bps to 0.18% in 2022, then plummeted by -56bps to 0.27% in 2023, then plummeted by -34bps to 0.37% in 2024, then plummeted by -58bps to 0.58% in 2025.
  • Its last three reported values are 0.58% in Q3 2025, 0.48% for Q2 2025, and 0.41% during Q1 2025.